recruitment into clinical trials Dr. Karen M. Barlow Associate - - PowerPoint PPT Presentation

recruitment into clinical trials
SMART_READER_LITE
LIVE PREVIEW

recruitment into clinical trials Dr. Karen M. Barlow Associate - - PowerPoint PPT Presentation

Lessons learned from Marketing Theory to improve recruitment into clinical trials Dr. Karen M. Barlow Associate Professor, University of Calgary Objectives Outline trends in trial recruitment Review marketing strategies Discuss the


slide-1
SLIDE 1

Lessons learned from Marketing Theory to improve recruitment into clinical trials

  • Dr. Karen M. Barlow

Associate Professor, University of Calgary

slide-2
SLIDE 2

Objectives

  • Outline trends in trial recruitment
  • Review marketing strategies
  • Discuss the relevant literature about how we

can use marketing to improve recruitment

  • Share our ideas
slide-3
SLIDE 3

Recruitment and Retention

  • One of the most important aspects of any

clinical trial

– Delays in recruitment costs money – Leads to uncertainty about relevancy of the trial – Decreased external validity – Time marches on – Drop out after randomization and loss to follow up ► decreased internal validity – Loss of backing from funding bodies

Time Budge get Qualit ity The “Golden Triangle” Of Project ct Management gement

slide-4
SLIDE 4

So how are we doing?

  • Multicentre trials between 1994 and 2002

– McDonald AM et al. Trials. 2006;7:9 – only 31% achieved original recruitment targets and – 53% requested grant extensions

  • More recently

– Sully BG, et al Trials. 2013;14:166. – recruitment has improved – 45 45% of trials als strugg ggle to r recruit uit their r sample e size and – ~1/3 needed d grant t extensio sions ns

slide-5
SLIDE 5

Who here is running a clinical trial?

  • How’s recruitment?
  • How’s retention?
slide-6
SLIDE 6

Barriers to participation

To name a f e a few

  • Public awareness
  • Risk vs. benefit
  • Cultural / language
  • Industry / Economic
  • Clinician (e.g. time, buy-in)
  • Parental (time, best tx)
  • Language of clinical trials

(randomization, equipoise)

  • Consent process

Children ldren

  • Children need to be protected
  • Understanding
  • Negative publicity
  • Informed assent
  • Parental decision makers
  • Teenagers
slide-7
SLIDE 7

Ma Mark rketing ting – th the e Definition Definition

  • Process:

– defining markets – quantifying the needs of the customer – determining the value – communicating these value propositions to “stakeholders”

» (A value proposition is a bundle of benefits offered that impels a customer to want to buy)

– delivering – monitoring

McDonald M, Wilson H. The new marketing: transforming the corporate future. Oxford: Butterworth-Heinemann; 2002

slide-8
SLIDE 8

5 stages of “marketing” a clinical trial

Gain the buy-in and devise systems for marketing Who? What do they need to sign up? Develop a 'value proposition' Convey the 'value proposition' to patients, medical personnel, agencies, advocacy groups To learn, through doing, develop more effective practices. To maintain momentum by renewing or upgrading 'the

  • ffer’, sustain

interest of agencies etc Francis D, Roberts I, Elbourne DR et al. Trials. 2007: 8:37

slide-9
SLIDE 9
  • Signaling worthiness:

– Buy-in likely when participants realize, and identify with, the potential benefits gained by the trial’s success

  • Simple processes:

– Simple processes reduces the costs (time effort money) of participation

  • Strategies for overcoming resistance
  • Adopting an explicit marketing plan:

– will need to be revised frequently – probably every

  • quarter. Separate plans for

– The Uninformed – The Unconvinced – The Laggards (Enroll, facilitate and target), – The Steady Performers (Reward, renew, upgrade and recognise) and – The Stars (Honour, learn from, and nourish).

Francis D, Roberts I, Elbourne DR et al. Trials. 2007: 8:37

The he Reference erence Mo Model del

slide-10
SLIDE 10
  • CRASH-2 Trial

– using ng the model to develop

  • p trial

al process esses es – CRASH-2 trial collaborators. Lancet. 2010;376:23-32

  • Txt2stop

p Tri rial al

– using ng the model as a diagn gnos

  • sti

tic c tool – all the new interventions fitted into the marketing framework tool and recruitment increased markedly – Free C, et al. Lancet. 2011;378(9785):49- 55

  • LIFE

FELAX LAX Trial

– using ng the model as an aud udit it tool – Speed C, et al. Health Technol Assess. 2010;14(52):1-251

  • Play Game Trial

al (diag iagno nostic stic tool)

slide-11
SLIDE 11

Recruitment ecruitment Op Opti timisa misation tion Mo Model del

Galli i L, Knight ht R, Rober ertson tson S, et et al. Trials

  • ls. 2014;15:

5:182 182

slide-12
SLIDE 12

Determine nature of problems: 7 P’s

  • Product (trial)
  • Price (costs/time/barriers)
  • Promotion/communication (e.g. mass media)
  • Place (convenient, preferable)
  • People

– research staff shape expectations, build trust and commitment between the trial and its participants

  • Processes

– actions required of participants to participate in the trial, ease of use is key. E.g. nature of the consent process

  • Physical environment

– participants will have greater confidence in a trial conducted in a well-cared for facility

slide-13
SLIDE 13

What barriers have you encountered?

slide-14
SLIDE 14

Recruitment ecruitment Op Opti timisa misation tion Mo Model del

  • Strengths

– Iterative and dynamic – Focuses on multiple learning events as emergent and on- going processes – Experiential

  • Weaknesses

– New – ?Only used in Txt2Stop

slide-15
SLIDE 15

Ma Mark rketing ting an and In Informat

  • rmation

ion Tec echnolo nology gy

  • MARKIT model

– IT, marketing, and clinical research – a single framework – to maximize recruitment, enrollment, engagement, and retention

  • Benefits

– ? reach larger and more diverse community of participants – help maximize limited resources – more cost-effective and efficient clinical trial management

  • Limitations

– ? tech savvy ? Generalizability – specialized staff with expertise in marketing and IT systems – Fewer face-to-face interactions ? Less engagement

Gupta a A, Calfas KJ, J, Mar arsh shal all l SJ, , et et al. Cont ntem empo porar rary y Clinical ical Tria ials. . 2015;42 ;42:1 :185-195

slide-16
SLIDE 16

Gupta a A, Calfas KJ, J, Mar arsh shal all l SJ, , et et al. Cont ntem empo porar rary y Clinical ical Tria ials. . 2015;42 ;42:1 :185-195

slide-17
SLIDE 17

Q-QA QAT – qu quan anti ti-quali qualitativ tative e ap appo point intment ment ti timing ing

  • A

A simple le tec echn hnique ue to iden entify tify key y rec ecrui ruitme tment nt issues ues in RCT? CT?

  • Methods:

– quantification of time spent discussing RCT and its treatments

  • using transcripts of audio-recorded recruitment appointments,

– targeted qualitative research to understand the obstacles to recruitment – feedback to recruiters on opportunities for improvement

Paramasivan S, Strong S, Wilson C, et al. Trials. 2015(16:88)

slide-18
SLIDE 18

What strategies have you employed to increase recruitment?

  • Stakeholder – patients, physicians, nurses, parents
  • Recruitment?
  • Retention?
slide-19
SLIDE 19

www.playgametrial.ca

slide-20
SLIDE 20
  • Building our brand

– Two large cohort studies – Product development – “the need” – Focus groups, online questionnaires, clinic patients – Stakeho holde lder r meets ets

  • Legitimacy

– Conference presentations – Cohort study of treatment response – Professional expertise – Tri-council funding

  • But issues with “product” and “buy

in” from professionals initially and

  • ver the counter availability
slide-21
SLIDE 21
  • Recrui

ruitment ent - Simple ple process?

  • cess?

– No. – Initially hard for families in ED to envision enrollment one month later – Other study ”competition” – Research in clinical environments eg FP office

  • Strategies to overcome problems

– Increased ED recruitment – reiterative – Paper to electronic, Consent to contact – Personal contact

  • Explicit recruitment plan

– ED, FP, sport societies – Webpages, twitter, FB – Product – plus MRI and cognitive testing

slide-22
SLIDE 22
  • Making the sale

– Advocates – Media (Radio, TV, internet, newspaper) – Sports meeting – Recurring events – Safety – Participant spokeskids at events

  • Maintaining engagement

– Xmas cards – Thank you gifts – Newsletters – Focus groups – Pictures and info for school projects – Clinic appointments – Recurrent meets with stakeholders (e.g. ED, TMS, MRI, CIHR, ACHF, ICRP)

slide-23
SLIDE 23

Potential problems: 7 Ps

  • Product (trial)
  • Price (costs/time/barriers)
  • Promotion/communication (e.g. mass

media)

  • Place (convenient, preferable)
  • People
  • Processes
  • Physical environment
  • A safe treatment but over-the-counter,

initially credibility

  • Once a day tx; Trial -time consuming;

invx offer reassurance

  • Where are the clients? Liaison with

ethics, Increasingly positive reviews

  • n Websites (need more promotion),

TV, ACHF, News, Treatment is at home

  • Excellent staff
  • Complex initially, reassurances of

weekly and medical follow-up

  • The fabulous Children’s Hospital
slide-24
SLIDE 24

Summary

  • Recruitment to clinical trials is a major issue
  • Strategies should be planned in the

development phase

  • Marketing strategies can be employed
  • Problems should be identified early on
  • Continual evaluation
  • Used our own examples to illustrate